- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A GP alleged a renal referral education meeting was disguised promotion of Trajenta (linagliptin). The Panel found insufficient evidence Trajenta was discussed…
A Sanofi haematology sales rep emailed a hospital clinician about Mozobil funding, stating an individual funding request to the PCT “will approve…
A hospital meeting discussion of the unpublished EFFICACY trial led to an implied message that there was no clinical reason to prescribe…
Pharmacosmos said a Ferinject ad claim “Non dextran carboxymaltose shell” breached Vifor undertakings about “dextran-induced hypersensitivity” messaging. PMCPA ruled the ad didn’t…
Vifor-backed NHS Alliance conference video about redesigning iron services was deemed promotional for Ferinject. Claims implied faster recovery and one-visit dosing, and…
Pfizer Ireland exhibited at an ISU meeting in Belfast held at a 5-star hotel with golf and a gala dinner in the…
Roche disclosed that a relations manager had been in a promotional role since Dec 2010 but had not taken/passed the ABPI Medical…
A Januvia leavepiece used a single linagliptin study chart that the Panel said gave an unbalanced view of efficacy and encouraged a…
Norgine’s Dantrium press release cited a survivor-only epidemiology study but implied reduced mortality and “ensure patient survival”. PMCPA found the mortality impression…
Complaint about UCB’s UK website: alleged failure to declare support to a patient organisation and failure to re-approve website content. Panel ruled…
Anonymous haematologist alleged a Chugai rep used inaccurate/misleading information about Granocyte, including extrapolating healthy donor data to neutropenia patients and NHS commissioning…
Allergan’s UK market research on hypothetical ready-to-use botulinum toxins was ruled promotional and disguised promotion. Breaches included missing prescribing information, pre-licence promotion…
A GP alleged Jinarc (tolvaptan) patient materials advertised a POM to the public and raised unfounded hopes. The Panel found the materials…
GSK admitted breaches after Incruse+Relvar digital ads appeared with blurred non-proprietary names, broken/incorrect PI links (Relvar PI missing) and some ads published…
PMCPA reviewed alleged late disclosure of trials for Caprelsa and Zinforo flagged in an ABPI-funded transparency study. Panel found the older Caprelsa…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.